Can I use afamelanotide and tesamorelin together?

There are no known direct drug interactions between them since they act on completely different systems. However, using both would only make sense if you had both EPP (or a porphyria) and HIV-associated lipodystrophy—an extremely rare scenario. You'd need explicit approval from your medical team, and the benefit would depend on proper management of both conditions.

Which peptide has fewer side effects?

Afamelanotide generally has a milder side effect profile: mainly injection-site irritation and occasional nausea. Tesamorelin carries more systemic effects due to elevated GH—carpal tunnel syndrome, joint pain, and glucose intolerance are more common. For most people, afamelanotide is better tolerated, but this depends on individual factors and close medical monitoring.

Are these peptides available for off-label use?

Both are prescription-only, FDA-approved medications. Off-label prescribing is legally permitted in the US but must be medically justified, documented, and monitored. Neither should be used for unapproved conditions without strong clinical rationale and expert oversight. Discuss any off-label interest with your prescribing physician.

How do I know which peptide I might need?

You don't choose between them—your diagnosis does. If you have a light-sensitive porphyria, your dermatologist will consider afamelanotide. If you're HIV-positive with metabolic complications, your HIV specialist will evaluate tesamorelin. Both require formal diagnosis and specialist management, not self-diagnosis.

Are these approved outside the US and EU?

Afamelanotide is FDA and EMA approved but not approved in Canada. Tesamorelin is FDA and EMA approved, but its Canadian approval was cancelled. Availability varies by region; check your local regulatory authority for status.

Afamelanotide vs Tesamorelin: Key Differences & Uses

Afamelanotide and tesamorelin are both FDA-approved peptides, but they work in entirely different ways and address different health concerns. Afamelanotide is a melanocortin receptor agonist used primarily for rare light-sensitive skin disorders, while tesamorelin is a growth hormone-releasing hormone (GHRH) analog designed to address lipodystrophy and metabolic changes in HIV patients. If you're comparing these two, you're likely trying to understand which one—if either—fits a specific health situation. This guide breaks down the evidence, regulatory status, and real differences between them.

What Is Afamelanotide?

Afamelanotide is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring signaling molecule in your body. It works by activating melanocortin-1 receptors on melanocytes—the cells responsible for producing melanin, the pigment that protects skin from UV damage.

Afamelanotide received FDA approval in 2014 specifically for treating erythropoietic protoporphyria (EPP), a rare genetic disorder where patients experience severe phototoxic reactions—blistering, burning, and scarring—after even brief sun exposure. The logic is straightforward: more melanin = more UV protection = fewer painful reactions.

Clinically, afamelanotide has been studied in 23 clinical trials with strong evidence supporting its use in EPP and related porphyrias. The peptide works systemically—you inject it subcutaneously, usually once every 10 days—and stimulates melanin production over days to weeks.

What Is Tesamorelin?

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog—a 44-amino acid peptide that signals your pituitary gland to produce and release more growth hormone (GH). Unlike afamelanotide, which acts on skin melanocytes, tesamorelin targets endocrine function.

The FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy—a condition where HIV-positive patients accumulate abdominal fat while losing fat elsewhere, disrupting metabolism and increasing cardiovascular risk. By boosting GH levels, tesamorelin helps redistribute fat, reduce visceral adiposity, and improve metabolic markers.

Tesamorelin has completed 11 clinical trials with robust evidence in HIV populations. The peptide is injected daily or twice daily and requires consistent dosing for effect.

Clinical Evidence & Regulatory Status

Afamelanotide

Regulatory Status:

FDA-approved (2014) for EPP and variegate porphyria (VP)
EMA-authorised under the trade name Scenesse
Not approved in Canada

Evidence Profile: Afamelanotide has strong A-grade evidence in its indicated population. A landmark double-blind randomized controlled trial published in The Lancet demonstrated that afamelanotide-treated EPP patients achieved significantly higher median phototoxic reaction–free days compared to placebo (16 vs 2 days per month). Patients also reported meaningful improvements in quality of life and sun-avoidance behavior. Safety data across 23 trials shows it's generally well-tolerated, with common side effects being mild injection-site reactions and nausea.

Tesamorelin

Regulatory Status:

FDA-approved (2010) for HIV-associated lipodystrophy
EMA-authorised under the trade name Egrifta
Regulatory approval cancelled in Canada

Evidence Profile: Tesamorelin carries A-grade evidence in HIV populations. A major 2020 meta-analysis of tesamorelin trials found consistent reductions in visceral adipose tissue (VAT)—the dangerous fat surrounding abdominal organs—with improvements in insulin sensitivity and lipid profiles. The magnitude of VAT reduction in responders ranges from 10–20%. Notably, benefits diminish if the peptide is stopped; effects are not permanent. Common side effects include injection-site reactions, carpal tunnel syndrome (from GH elevation), and joint pain.

Key Mechanistic Differences

Understanding how these peptides work clarifies why they're used for completely different conditions:

Afamelanotide:

Target: Melanocortin-1 receptors on skin melanocytes
Primary effect: Increased melanin synthesis
Onset: Gradual; protective effect builds over 1–2 weeks
Duration: Effect persists weeks after injection stops
Best for: Light-sensitive skin disorders (porphyrias, xeroderma pigmentosum)

Tesamorelin:

Target: GHRH receptors on anterior pituitary somatotroph cells
Primary effect: Elevated growth hormone secretion
Onset: Days; metabolic changes accumulate over weeks to months
Duration: Reverses quickly when stopped (GH returns to baseline)
Best for: Metabolic complications in HIV, abdominal fat redistribution

Because they act on different tissues via different mechanisms, there's minimal overlap in clinical use cases. A patient with EPP has no reason to use tesamorelin, and an HIV patient with lipodystrophy won't benefit from afamelanotide's skin-protective effects.

Off-Label and Investigational Uses

Afamelanotide: Research has explored its use in other porphyrias and polymorphous light eruption (PLE), though these remain largely investigational outside its approved indication. Some anecdotal interest exists around photoaging and cosmetic skin protection, but clinical evidence is limited.

Tesamorelin: Beyond HIV lipodystrophy, preclinical and early clinical data suggest potential in age-related GH decline and metabolic dysfunction, though such uses remain investigational and are not approved. Athletes have misused it, but it's banned in sport due to its ergogenic effects.

Who Each Is Best Suited For

Afamelanotide is appropriate if you:

Have been diagnosed with erythropoietic protoporphyria (EPP) or variegate porphyria (VP)
Experience severe phototoxic reactions that disrupt quality of life
Have failed or are intolerant to sun avoidance alone
Are willing to commit to regular (every 10-day) injections

Tesamorelin is appropriate if you:

Are HIV-positive and have been diagnosed with lipodystrophy (abdominal fat accumulation, peripheral lipoatrophy)
Have metabolic complications (elevated triglycerides, insulin resistance, cardiovascular risk)
Can maintain consistent daily or twice-daily injection regimen
Are monitored by an HIV specialist or endocrinologist

Practical Considerations

Cost & Access: Both peptides are expensive and typically require insurance or specialty pharmacy support. Afamelanotide (Scenesse) is often available through patient assistance programs for EPP patients. Tesamorelin (Egrifta) has similar support but is now rarely used in developed countries as combination antiretroviral therapy has made lipodystrophy less common.

Monitoring: Afamelanotide requires minimal lab monitoring once approved. Tesamorelin demands regular GH, insulin, and lipid monitoring, plus screening for carpal tunnel and glucose intolerance.

Onset & Timeline: Afamelanotide's benefit is gradual but durable. Tesamorelin requires consistent dosing over months for full benefit, with rapid reversal if stopped.

The Bottom Line

Afamelanotide and tesamorelin represent two solved problems in modern medicine—rare genetic skin disorders and metabolic complications of HIV—but they're fundamentally different drugs. Choosing between them isn't really a choice: they address different diseases in different populations with different mechanisms. If you're considering either, you've almost certainly been diagnosed with a specific condition, and your healthcare provider will have recommended the appropriate peptide based on evidence and your individual needs.

The real takeaway is that both are FDA- and EMA-approved with solid clinical evidence, making them part of legitimate treatment options rather than experimental compounds. That level of regulatory validation matters.

Related Peptides

If you're exploring peptide therapeutics, you might also want to learn about peptide therapeutics basics, how melanocortin receptor agonists work differently, or growth hormone-releasing peptides like sermorelin, which is similar to tesamorelin but with a different profile.

Afamelanotide vs Tesamorelin: What's the Difference?